Obesity and knee OA: what review found

A 2026 narrative review argues that weight management belongs near the center of primary care for people who have obesity and knee osteoarthritis. The paper is not a clinical trial and reports no new patient outcomes. It combines a targeted PubMed search with practical recommendations, then points to lifestyle evidence and the STEP 9 trial of semaglutide as reasons to study obesity medicines in this setting^[1].

The review connects two common conditions

Nelson and colleagues describe lifetime knee osteoarthritis risk as approximately twice as high in people with obesity as in people without obesity. They conducted a targeted PubMed search for literature on weight loss among patients with both conditions. The authors conclude that caloric restriction combined with exercise has a strong evidence base for improving pain, physical function and quality of life, although maintaining those programs can be difficult^[2].

This is a narrative review rather than a systematic review or meta-analysis. The abstract does not report a search date, complete search strategy, screening flow or formal assessment of study quality. That makes it useful as a clinical overview, but not as a pooled estimate of how much any intervention changes pain or function. Its recommendations reflect the literature the authors selected and interpreted. They should be read as an evidence map for primary care, not as a new treatment comparison.

STEP 9 supplies the semaglutide result

The phase 3 evidence behind the review's semaglutide discussion comes from STEP 9. That double-blind randomized trial enrolled 407 adults with obesity and moderate knee osteoarthritis at 61 sites in 11 countries. Participants received semaglutide 2.4 mg or placebo for 68 weeks, alongside counseling on physical activity and a reduced-calorie diet. The two primary endpoints were percentage change in body weight and change in WOMAC pain score, where higher scores indicate worse pain^[3].

Mean body weight changed by minus 13.7% with semaglutide and minus 3.2% with placebo. Mean WOMAC pain score changed by minus 41.7 points with semaglutide and minus 27.5 points with placebo. The semaglutide group also had a larger improvement in the SF-36 physical-function score, 12.0 points compared with 6.5 points. Each comparison had a p value below .001^[3]. These are group averages from a selected trial population, not a forecast for an individual patient.

Serious adverse events occurred at similar rates in the two trial groups. Permanent discontinuation because of adverse events occurred in 6.7% of participants assigned semaglutide and 3.0% assigned placebo, with gastrointestinal disorders the most common reason^[3]. STEP 9 was funded by Novo Nordisk, the manufacturer of semaglutide. The trial tested one medicine in a defined population; it did not test all obesity medicines or all people with knee pain.

Pain improvement does not prove joint repair

STEP 9 showed greater weight loss and pain improvement over 68 weeks, but the abstract does not establish that semaglutide changed joint structure or slowed osteoarthritis progression. Pain can change through reduced mechanical load, altered activity, systemic effects or other pathways. The randomized design supports a treatment effect on the measured outcomes. It does not identify how much of the pain difference came from weight loss, a direct drug effect or changes that followed improved mobility.

The 2026 review calls obesity medicines an emerging addition to knee osteoarthritis management and says more clinical evidence is needed before wide adoption. It identifies several open questions: treatment duration, longer-term tolerability, preservation of functional muscle mass and weight regain after medicine withdrawal. Those are not minor details. Knee osteoarthritis already limits movement for many patients, so changes in muscle function and the durability of symptom relief affect how a weight-management strategy should be judged.

Primary care still needs a combined plan

The review does not replace exercise and dietary support with a prescription. It places obesity medicines inside a broader program that includes screening, risk stratification, communication, guideline use and multidisciplinary care. That framing fits the evidence it summarizes. STEP 9 added semaglutide to counseling on physical activity and a reduced-calorie diet, so the trial does not isolate a medicine-only pathway outside supportive care.

Treatment choices also need to account for why a knee hurts, the severity of osteoarthritis, other illnesses and the person's ability to participate in movement-based care. A narrative review can organize those considerations, but it cannot specify the best sequence for every patient. The paper's practical focus should not be mistaken for a dosing guide. The literature reports what researchers administered; decisions about starting, continuing or stopping a prescription medicine require a qualified healthcare professional who can assess the individual case.

What the review can and cannot support

The review supports three bounded conclusions. Obesity and knee osteoarthritis often overlap. Weight loss through diet and exercise can improve symptoms and function, although adherence is difficult. STEP 9 found that semaglutide added to lifestyle counseling produced greater average weight loss and pain reduction than placebo over 68 weeks. The review does not establish a universal first-line medicine, prove structural joint repair or settle long-term safety and durability.

Readers looking for molecule-level background can use the semaglutide evidence page. The next useful studies would separate pain change from structural outcomes, follow muscle function and weight regain beyond the trial period, and compare integrated care pathways rather than treating medicine, exercise and nutrition as unrelated choices. Until then, STEP 9 is a strong randomized result inside a narrower population, while the 2026 review remains an interpretive guide for primary care.